Home > Oncology > SABCS 2021 > Phase 1–3 Trials > Entinostat plus exemestane improves progression-free survival in Chinese patients

Entinostat plus exemestane improves progression-free survival in Chinese patients

Presented By
Prof. Binghe Xu, Chinese Academy of Medical Sciences, China
Conference
SABCS 2021
Patients with advanced hormone receptor (HR)–positive/HER2-negative breast cancer derived greater progression-free survival (PFS) benefit when treated with entinostat plus exemestane versus matched placebo, according to results from a Chinese, phase 3 study. Entinostat is a potent, once weekly, orally bioavailable, class 1 selective histone deacetylase inhibitor. In breast cancer, disruption of oestrogen-mediated signalling results in acquired resistance to hormonal therapy. Entinostat is hypothesised to re-sensitise these cells to endocrine treatment. Prof. Binghe Xu (Chinese Academy of Medical Sciences, China) presented results of a double-blind, placebo-controlled, phase 3 (NCT03538171) trial evaluating the efficacy and safety of entinostat plus exemestane versus placebo plus exemestane in patients with HR-positive/HER2-negati...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on